Sirnaomics
13
1
2
10
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
7.7%
1 terminated/withdrawn out of 13 trials
90.9%
+4.4% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 10 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (13)
STP705 Injection for Submental Fat Reduction
Role: lead
Ph. 1, Evaluation of Safety, Tolerability, PK, Anti-tumor Activity of STP707 IV in Subjects With Solid Tumors
Role: lead
Safety, Tolerability, Pharmacokinetics, Immunogenicity and Efficacy of STP705 in Adult Patients With Hypertrophic Scars
Role: lead
Single Ascending Dose of FXI-GalNAc-siRNA in Healthy Subjects
Role: lead
A Study for Safety and Efficacy Evaluation of Various Doses of STP705 in Reducing Keloid Recurrence
Role: lead
Safety, Tolerability, PK, Anti-Tumor Activity of STP705 in Subjects With Advanced/Metastatic or Surgically Unresectable Solid Tumors Who Are Refractory to Standard Therapy
Role: lead
A Study to Evaluate Safety, Tolerability of Subcutaneous Injection in Adult Subjects Undergoing Abdominoplasty
Role: lead
Open Label, Dose Escalation Study for the Safety and Efficacy of STP705 in Adult Patients With Basal Cell Carcinoma
Role: lead
Study to Evaluate Safety, Efficacy of Intralesional Injection of STP705 in Adults With Facial isSCC
Role: lead
A Study to Evaluate Safety, Efficacy of Intralesional Injection of STP705 in Patients With isSCC
Role: lead
A Study of STP707 Administered by IV in Healthy Subjects
Role: lead
Open Label, Dose Escalation Study for the Safety and Efficacy of STP705 in Adult Patients With isSCC
Role: lead
A Randomized Study to Evaluate the Safety and Efficacy of Various Doses of STP705 in Subjects With Hypertrophic Scar
Role: lead
All 13 trials loaded